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ABSTRACT
Prostate cancer (CaP) is the most commonly diagnosed cancer in males. There have been dramatic technical advances in
radiotherapy delivery, enabling higher doses of radiotherapy to primary cancer, involved lymph nodes and
oligometastases with acceptable normal tissue toxicity. Despite this, many patients relapse following primary radical
therapy, and novel treatment approaches are required. Metal nanoparticles are agents that promise to improve diagnostic
imaging and image-guided radiotherapy and to selectively enhance radiotherapy effectiveness in CaP. We summarize
current radiotherapy treatment approaches for CaP and consider pre-clinical and clinical evidence for metal nanoparticles
in this condition.
Prostate cancer (CaP) is the most commonly diagnosed
cancer in males and is responsible for more than 10,000
deaths each year in the UK.1 Technical advances in radio-
therapy delivery, including image-guided intensity-modulated
radiotherapy (IG-IMRT), have enabled the delivery of higher
radiation dose to the prostate, which has led to improved
biochemical control. Further improvements in cancer imag-
ing during radiotherapy are being developed with the advent
of MRI simulators and MRI linear accelerators.2–4
Nanotechnology promises to deliver signiﬁcant advance-
ments across numerous disciplines.5 The widest scope of
applications are from the biomedical ﬁeld including exoge-
nous gene/drug delivery systems, advanced biosensors, tar-
geted contrast agents for diagnostic applications and as direct
therapeutic agents used in combination with existing treat-
ment modalities.6–11 This diversity of application is especially
evident within cancer research, with a myriad of experi-
mental anticancer strategies currently under investigation.
This review will focus speciﬁcally on the potential of metal-
based nanoparticles to augment the efﬁcacy of radiotherapy
in CaP, a disease where radiotherapy constitutes a major
curative treatment modality.12 Furthermore, we will also
address the clinical state of the art for CaP radiotherapy and
consider how these treatments could be best combined with
nanotherapeutics to improve cancer outcomes.
CURRENT STATE OF THE ART IN PROSTATE
CANCER DIAGNOSIS AND TREATMENT
The management of CaP is changing rapidly with advances
occurring in diagnosis, imaging and treatment. Most males
present with localized rather than advanced CaP at di-
agnosis. Current stratiﬁcation methods place patients into
low-, intermediate- and high-risk prognostic categories
based on prostate-speciﬁc antigen levels, local staging and
Gleason score.13
Males with low-risk CaP are increasingly managed with
active surveillance, with large studies reporting 10-year cancer-
speciﬁc survival rates of .98% with this management
approach.14 In this cohort, 75.6% of males were treatment
free after 5 years of active surveillance.15 The role of multi-
parametric MRI in active surveillance has been deﬁned, and
nanotechnology offers the potential for better imaging bio-
markers to monitor patterns of disease.16,17 The role of super-
paramagnetic iron oxide nanoparticles (SPIONs) in MRI
nodal staging for CaP has previously been demonstrated.18
Intermediate CaP is a heterogeneous group, where treatment
options include active surveillance, radical prostatectomy,
external beam radiotherapy (EBRT), brachytherapy (BT)
alone or in combination with androgen deprivation therapy
(ADT) and/or EBRT. Randomized controlled trials of dose-
escalated EBRT, with doses of 74.0–79.2Gy in conventional
(1.8–2Gy) fractions, have demonstrated 5-year biochemical
progression-free survival of 64–80.4%.19–22 These studies have
demonstrated improved biochemical control compared with lower
doses of EBRT at the expense of higher rates of bowel and urinary
toxicity. EBRT requires linear accelerators capable of producing
photon energy spectrums commonly peaking at 6 or 10MV to
deliver an adequate radiation dose to the prostate gland, which is
situated centrally within the pelvis. Pre-clinical studies have sug-
gested that metal nanoparticle sensitization occurs even at mega-
voltage (MV) energies, where Compton effects dominate.11,23
BT is radiotherapy using sealed radioactive sources placed next
to the skin, inserted into a body cavity or, through needles, into
tissues (interstitial BT).24 There are compelling reasons for
utilizing metal nanoparticles with kilovoltage (kV) photon en-
ergies where the photoelectric effect is dominant [energy
deposited 2 atomic number4 (Z4)], a concept supported by
several theoretical studies (Figure 1).25,26 BT commonly utilizes
kV radiation sources, for example iodine-125 (125I; 35.5 keV
g-rays, t½ 30 days), and has been shown to result in excellent
biochemical control rates of 75–98% at 5 years.27 The direct
placement of permanent radioactive sources into the prostate
gland increases conformality of treatment compared with EBRT,
resulting in enabling delivery of higher doses of radiation to the
prostate with acceptable normal tissue toxicity. High-dose-rate
(HDR) BT is commonly combined with EBRT in patients with
unfavourable intermediate risk CaP (Gleason 413, .50%
positive cores). An iridium-192 (205–612 keV g-rays, t½ 74 days)
source is commonly used for treatment. With this approach,
a single 15-Gy treatment of HDR BTwas combined with 37.5 Gy
in 15 fractions of EBRT resulting in 97% of patients becoming
disease free at 5 years.28
Radiobiological studies suggest that CaP may have a lower a/b
ratio than surrounding normal tissues, making it more sensitive
to high dose-per-fraction radiotherapy.29 An alternative method
of biological dose enhancement is hypofractionation, which
exploits the low a/b ratio observed in CaP. Recent technological
advances have enabled the development of stereotactic ablative
radiotherapy (SABR). Clinical studies of SABR have demon-
strated excellent biochemical control rates with acceptable
treatment-related toxicity.30 Longer follow-up of existing studies
is required and Phase III clinical trials are under way.31 If radical
CaP treatments of ﬁve fractions or less are demonstrated to have
efﬁcacy equal to or better than conventional radiotherapy, then
the use of radiosensitizing nanoparticles, delivered intravenously
or intratumorally, becomes feasible with a reduced likelihood of
off-target effects from multiple administrations.
In patients with high-risk localized CaP, a combination of
radiotherapeutic and systemic therapies is generally utilized to
optimize cancer control. A landmark study demonstrated that
the addition of ADT to EBRT improved 5-year overall survival
from 62% in patients treated with EBRT alone to 78% in
patients treated with combined therapy.32 Similarly, more recent
trials demonstrated the combination of EBRT with ADT im-
proved overall survival when compared with ADT alone.33
Nanoparticles are being widely investigated as drug carriers to
enhance the effectiveness of systemic therapy with some agents
in early-phase clinical trials.34
Radiotherapeutic advances in metastatic CaP have paralleled
those in localized disease. Technological advances have enabled
the development of SABR for areas of oligometastatic disease,
delivering radical doses of radiation in a small number of
Figure 1. Schematic representation of radiation interactions when an incident photon interacts with a high atomic number (Z)
material and their downstream applications in radiotherapy. (a) Compton scattering occurs when an incident photon is scattered by
a weakly bound outer-shell electron causing the photon to be deflected and lose energy, which is then transferred to the electron
that is ejected from the atom. (b) Photoelectric ionization occurs when an incident photon is fully absorbed by an inner-shell
electron, transferring its energy to it and causing it to be ejected from the atom. (c) Outer-shell electrons can fall into this vacancy,
liberating further energy, often in the form of additional secondary Auger electrons.
BJR Coulter JA et al
2 of 9 birpublications.org/bjr Br J Radiol;88:20150256
treatment fractions.35 The a-emitter radionuclide radium-223
has been shown to prolong survival compared with the best
supportive care (14.9 vs 11.3months; HR, 0.70; p5 0.002) in
patients with metastatic castrate-resistant CaP.36 This systemic
treatment is administered intravenously, accumulating at sites of
bony metastatic disease and delivering highly damaging low-
range a particles to these sites. Multifunctional nanoparticles
utilized as drug delivery agents could enhance the speciﬁcity and
effects of current systemic therapies used in CaP.
Although IG-IMRT has reached unprecedented levels of accu-
racy, there is signiﬁcant potential for further improvement of
radiotherapy delivery with the use of MRI. MRI simulation has
a number of beneﬁts over computerized tomography for treat-
ment planning, enabling dose estimation in deformable soft
tissues. It is likely that dose-painting and adaptive radiotherapy
approaches will become the standard of care in the near future.
International efforts are ongoing to develop an MRI-linac sys-
tem for online, real-time soft-tissue image guidance.2–4 Multi-
functional gadolinium (Gd)-based agents that can be used for
image contrast and radiation enhancement have signiﬁcant po-
tential to deliver innovative approaches in radiation oncology
that may translate to human health gains.
METAL NANOPARTICLES
With the chemistry for metal nanoparticle synthesis well estab-
lished, the ultimate choice of the core material depends largely on
the downstream application. Attributes vary depending upon the
composition of the core material but typically include superior
biocompatibility relative to many existing pharmaceutical agents,
tunability of nanoparticle size, shape and charge during the
synthesis procedure and the relative ease with which additional
functional groups can be conjugated to the surface.37 Examples
of functionalized nanoparticles are shown in Figure 2.
Iron-based nanoparticles
SPION, when adequately stabilized with organic surface coatings,
can be homogeneously dispersed in suspensions known as ferro-
ﬂuids. Following systemic administration, these colloid suspen-
sions interact with external magnetic ﬁelds for imaging or, in some
instances, to actively recruit nanoparticles to speciﬁc locations.41
Early preparations of SPION were used as reticuloendothelial
system MRI contrast agents that produce local inhomogeneities in
the magnetic ﬁeld during imaging. MRI contrast efﬁcacy is
established by reducing transverse relaxation (T2), where the rate
of proton relaxivity is proportional to the iron atom concentration,
thus providing negative contrast in MR images. While the
Figure 2. A schematic represention of a bi-functionalized, polyethylene glycol (PEG) stabilized gold-based nanoparticle (AuNP)
including a variety of prostate cancer-specific active targeting moieties. NHS, N–hydroxysuccinimide.9,38–40
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enhanced imaging capabilities of these preparations are clearly
evident in the highly phagocytic environment of the liver, spleen
and bone marrow, their application is limited with respect to the
ultrasensitive detection of CaP for both localized disease and more
speciﬁcally micrometastasis. To address this, several iron oxide
nanoparticle (ION) preparations have been functionalized with
CaP-targeting ligands with the aim of elevating intratumoral
nanoparticle accumulation. Prostate-speciﬁc membrane antigen
(PSMA) is a valid target for speciﬁc CaP targeting.42 While normal
prostate epithelium tissue expresses alternative cytosolic splice
variants of PSMA, the transmembrane form is signiﬁcantly ele-
vated levels in CaP tissue, and has been shown to increase with
Gleason grade.43 Importantly, this mechanism for CaP tumour
selectivity is not restricted to the primary tumour, with lymph
node and bone metastatic deposits in the castrate-resistant setting
also exhibiting elevated PSMA expression.38,44 Tse et al45 have
recently developed an antibody (J591)–iron oxide conjugate
designed to target an extracellular epitope of PSMA, with the aim
of developing a superior CaP-MRI contrast agent. The speciﬁc
targeting efﬁcacy of J591 was well established from earlier radio-
labelled J591 studies.46,47 The focus of the present study was to
determine that antibody conjugation did not impair targeting ef-
ﬁcacy, along with demonstrating improved tumour-speciﬁc MRI
contrast and minimal cytotoxicity. Using an orthotopic LNCaP
(PSMA-expressing) xenograft model, the authors reported strong
negative contrast following intravenous (i.v.) injection of J591-
IONs at a concentration of 6mg kg21 within 2 h. Furthermore,
nanoparticles were retained within the tumour for at least 24 h of
administration; effects that were not achieved using stabilized,
untargeted control preparations. This pre-clinical study clearly
demonstrates the advantage of active targeting approaches rather
than depending on passive accumulation owing to the enhanced
permeability and retention (EPR) effect. However, it should be
noted that signiﬁcant quantities of both passive and targeted
nanoparticles were observed post-mortem within the spleen, in-
dicating that stealth strategies could be further optimized to in-
crease circulation time and, as a direct consequence, tumour
loading.
PSMA-targeted IONs as thermal therapy agents have also been
recently reported. Using an alternative chemical synthesis pro-
cedure, bionized nanoferrite clusters were stabilized using
polyethylene glycol (PEG) and targeted with a pre-validated
small molecule inhibitor of PSMA.48,49 In this study, the authors
developed isogenic PC3-PSMA-positive and negative sub-
cutaneous xenograft tumour models, reporting PSMA-positive
tumour accumulation within 2 h of administration, with maxi-
mum intratumoral concentrations achieved 48h post-injection.49
Central to their therapeutic efﬁcacy was the formation of
nanoclusters yielding enhanced heat production owing to vari-
ous magnetodynamic processes (hysteresis, Ne´el switching and
frictional contributions).50 Previously, exposure of clustered
magnetic nanoparticles to an alternating magnetic ﬁeld at a ﬁxed
frequency of 150 kHz facilitated near-complete regression of
MTG-B murine breast xenograft models by producing intra-
tumoral temperatures up to 55°C.51 Therefore, applying this
approach to a PSMA-expressing CaP is hypothesized to confer
signiﬁcant therapeutic beneﬁt.49 However, despite improved
targeting efﬁcacy, only 4.36 0.4% of the injected dose per gram
of tissue accrued within the tumour. This raises questions over
the clinical applicability of this strategy, speciﬁcally with refer-
ence to limiting heat production and conductance beyond the
target volume. Off-target effects were observed when nano-
clusters generated rectal temperatures in excess of 41.5°C, with
continued heat production after the shut down of the alternating
magnetic ﬁeld owing to conductance.51,52 Clearly, further re-
ﬁnement is required before early-phase clinical trials can begin.
Iron possesses a relatively low atomic number (Z5 26), unlike
metals with higher atomic numbers such as Gd (Z5 64), platinum
(Z5 78) and gold (Au; Z5 79); as such, the magnitude of the
mass absorption coefﬁcient and subsequent ampliﬁcation of ra-
diation effects (radiosensitization) is expected to be limited. De-
spite this, several authors have reported signiﬁcant in vitro CaP
radiosensitization using both kVand MV X-ray sources.53,54 Cross-
linked dextran-coated IONs were avidly endocytosed by both
HeLa and EMT-6 cells, producing a maximum reduction in cell
viability of 18% following 48h of coculture with the nanoparticles.
The signiﬁcance of this relatively low-toxicity proﬁle is further
heightened when considering the radiosensitization potential,
generating mean radiation dose enhancement factors (DEFs) of
1.43 and 1.36 in HeLa and EMT-6 cells, respectively. Subsequently,
Khoei et al54 reported DEFs of 1.22 following megavoltage irra-
diation in DU145 CaP cells in vitro, using a chemically analogous
nanoparticle. This provided proof-of-concept data that nano-
particles with an iron oxide core could potentially prove beneﬁcial
using clinically applicable radiation sources, while limiting the off-
target effects associated with hyperthermia. Licensed clinical
examples of such preparations that include Feridex and Resovist
are already in clinical use as contrast agents.55,56
Gadolinium-based nanoparticles
Current MRI techniques rely on the i.v. injection of a para-
magnetic contrast agent most commonly based on Gd chelates,
as Gd has even unpaired electrons and a relatively long re-
laxation time. Most of these agents are Gd chelates, such as
Gd-diethylenetriaminepenta-acetate (Gd-DTPA), which are non-
diffusible blood pool tracers captured soon after bolus injection
by haemodynamic signals depending on proton relaxation times
and then transformed to an MR signal.57,58
In addition to the paramagnetic features of Gd ions, their rel-
atively high atomic number suggests they may offer additional
advantages as radiosensitizers at MV energies. In terms of the
development of Gd-based nanoparticle platforms for improved
MRI and radiotherapy, recent studies have synthesized crystal-
line nanoparticles, polymeric micelles or functionalized different
types of nanoparticles with Gd chelates or ions.59,60
Gd-based radiosensitization has classically been demonstrated by
Gd(II) texaphyrin (Gd-tex), a porphyrin-like macrocycle that
forms highly stable complexes with metal cations.61 Gd-tex has
been shown to be well tolerated in a Phase-1 single-dose trial and
has been investigated as a radiotherapy adjuvant in later phase
trials for advanced solid malignancies of the brain, lung and
prostate.62 A number of Gd-based nanoparticle platforms have
demonstrated potential for enhancing both MRI contrast and
radiotherapy efﬁcacy. Tokumitsu et al63,64 have developed Gd-loaded
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chitosan nanoparticles composed of Gd-DTPA and chitosan, a nat-
urally occurring biocompatible polysaccharide, for use in Gd neu-
tron capture therapy that utilizes g-rays and electrons emitted from
157Gd (n,g) 158Gd decay. These particles have shown high cell af-
ﬁnity in vitro and signiﬁcant tumour growth delay by neutron
capture reaction when delivered by intratumoral injection in mice
bearing B16F10 malignant melanoma tumours.
Tillement and co-workers59 have developed the AGuIX® nano-
particle platform consisting of sub-5 nm Gd chelates (either
diethylenetriaminepenta-acetate or 1,4,7,10-tetra-azacyclodo-
decane-1-glutaric acid-4,7,10-triacetic acid covalently bonded
a polysiloxane matrix) (Figure 3). Pre-clinical studies have
demonstrated tolerability and excellent biodistribution patterns
for diagnostic and therapeutic purposes.59 These ﬁndings have
been accompanied with demonstrations of radiosensitizing
effects with DEFs from 1.1 to 2.5 in a range of tumour models
including the prostate.16,60
These experimental studies demonstrating Gd as a radiation
sensitizer are further supported by a recent Monte Carlo sim-
ulation study. Zhang et al65 calculated DEFs as a function of Gd
concentration for 6-MV photons with and without the use of
a ﬂattening ﬁlter and for HDR BT with an iridium-192 source.
The study predicted concentration-dependent dose enhance-
ment for Gd-containing materials in HDR BT and 6-MV ﬂat-
tening ﬁlter-free EBRT at concentrations .5mgml21, higher
than those currently used in the clinic.
Gold-based nanoparticles
Few inorganic core materials have attracted as much attention as
Au, an effect largely owing to its physical characteristics that in-
clude biocompatibility, ease of production, functionalization,
large surface area and superior mass energy absorption owing to
its high atomic number relative to soft tissue. The latter property
warrants the development of Au-based nanoparticles (AuNPs) as
effective X-ray contrast agents. Diagnostic X-ray imaging is
Figure 3. Summary of the physicochemical properties of the AGuIXâ nanoparticle platform. (a) Schematic representation of AGuIX
nanoparticles. The particles display a high Gd content (15%wt) with an average molecular mass of 8.7 kDa and a sub-5nm size. (b)
The hydrodynamic diameter distribution of AGuIX particles determined by dynamic light scattering indicating an average size of
3nm. (c) Electrospray ionization mass spectrometry measurements of AGuIX particles recorded on a global spectrum. The inset
indicates the spectrum generated after deconvolution with a multiplicative correlation algorithm. (d) Temporal evolution of the
longitudinal relaxation (r1) for various concentrations of AGuIX particles related to their stability in human serum. Data were fitted to
a monoexponential decay model.
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typically performed at energies ,200 keV, with the Compton and
photoelectric effect dominating photon absorption. Using 100-
keV X-rays, Au will provide approximately 2.7-fold more contrast
than iodine (I) (Au5 5.16 cm2 g21; I5 1.94 cm2 g21), the most
commonly utilized X-ray contrast agent.66 The ﬁrst use of AuNPs
to improve image contrast was reported by Hainfeld et al,9 who
described increased delineation of the vasculature, reduced bone
interference and extended imaging times with no adverse events
up to 1 month post administration. Since then, the list of po-
tential targets and applications has grown exponentially with 42%
of all nanoparticle publications (total 330,000 articles) since 2010
including Au within the article ﬁeld. As with other nanoparticle
preparations, surface modiﬁcations have been reﬁned to improve
targeting and therapeutic efﬁcacy. Gastrin-releasing peptide
receptors are highly expressed on various tumour types, including
breast and prostate carcinomas, and exhibit a high binding af-
ﬁnity towards bombesin (BBN) peptides. Chanda et al67 de-
veloped BBN conjugated AuNPs to speciﬁcally improve image
contrast of prostate tumours. In vitro assessment of AuNP-BBN
receptor binding using radioiodinated displacement assays dem-
onstrated gastrin-releasing peptide receptor speciﬁcity, with IC50
(minimum 2.45mgml21) concentrations inversely correlated
with AuNP surface coverage of the peptide. Furthermore, in-
traperitoneal administration of the nano-conjugate was shown
to limit the uptake by the reticuloendothelial compartment,
thereby extending the circulation time and tumour accumu-
lation. This resulted in a signiﬁcant and prolonged (up to 48 h)
post-administration increase in X-ray contrast, highlighting the
potential beneﬁt of molecular targeted nanotherapeutics.
As described previously, PSMA is an attractive target for CaP
molecular therapeutics. AuNPs functionalized with doxorubicin-
loaded aptamers have been developed for both diagnostic and
therapeutic applications. LNCaP cells expressing the PSMA re-
ceptor exhibited a 4-fold increase in CT intensity (Hounsﬁeld
units: LNCaP-130HU vs PC3-28HU) relative to PC3 cells lacking
PSMA receptors. In addition, therapeutic efﬁcacy of drug-loaded
nanoparticles was reported to produce equivalent reductions in cell
viability in PSMA-expressing cells as equimolar quantities of free
doxorubicin.68 Recently, the high electron dense properties of Au
have been exploited to develop a superior radio-opaque ﬁducial
tissue marker. In this instance, PEGylated AuNPs were combined
with sucrose acetate isobutyrate to form a nanogel. Evaluated using
an MRI murine model, the AuNP nanogel produced high CT
contrast and excellent stability. The biocompatibility of this
ﬁducial system was also demonstrated with no evidence of cy-
tokine (interferon-g, interleukin-6, or tumour necrosis factor a)
stimulation associated with an innate immune cell response over
a 12-week period.
Early evidence of therapeutic beneﬁt attributed tumour growth
inhibition to alternations in cell cycle regulation.69 Glucose-capped
AuNPs were avidly endocytosed into DU145 CaP cells exhibiting
no signiﬁcant cytotoxicity as a monotherapy. However, when
combined with a 2-Gy dose of radiation (Cs137 g-source), sur-
vival was reduced by 64% as compared with radiation alone.
Radiosensitization was credited to an accelerated G0/G1 phase
along with cell-cycle arrest in the more radiosensitive G2/M
phase, effects driven by a reduction in p53 and cyclin A, key
regulators of the cell cycle. With several groups reporting con-
vincing in vitro AuNP radiosensitization,23,39,69–71 the challenge of
translating this application into effective clinical agents remains.
Shukla et al72 developed b-emitting (bmax, 0.96 MeV; t1/2, 2.7
days) radioactive AuNPs conjugated with epigallocatechin-gallate
(EGCg), a phytochemical component extracted from green tea
that exhibits a high binding efﬁciency for the laminin receptor
(Lam 67R), overexpressed on many prostate tumours. The
198AuNP-EGCg nanoparticle was designed for direct intratumoral
injection, with the targeting ligand promoting endocytosis within
the tumour, while limiting passive loss of the particles into the
systemic circulation. This is central to the clinical applicability of
this strategy, as the b-particle emission has a tissue penetration
range of 11mm, which would likely induce dose-limiting toxicity
if distributed within the systemic circulation. Following a com-
prehensive pharmacokinetic and tumour retention study, 70% of
the total injected dose was retained within the tumour 24h post
administration, with minimal leakage into non-target organs and
the blood. Furthermore, potent therapeutic efﬁcacy was reported
using a PC3 unilateral ﬂank xenograft model. A single intra-
tumoral injection of 198AuNP-EGCg (approximately 5MBq)
supressed tumour growth by 4-fold on Day 18 compared with
control animals (untreated and EGCg only), an effect that was
maintained for a 5-week period. Upon sacriﬁce, 37.4% of the
injected dose was retained within the tumour, with no treatment-
associated reduction in the white blood cell compartment, nor
any dose-limiting accumulations of 198AuNP-EGCg in peripheral
organs. Despite the relative success of this strategy, non-target
radiation damage remains a signiﬁcant concern that requires
further pre-clinical evaluation. For localized CaP, MRI targeted,
transperineal, direct intratumoral injection under local anaes-
thetic is feasible.
Pre-clinical studies have investigated combining AuNPs with
commonly used BT sources, a concept supported by several
theoretical studies.25,26 Ngwa et al40 reported the ﬁrst experi-
mental evidence in support of this strategy. In this in vitromodel,
HeLa cells were exposed to 125I BT seeds and 200mgml21 AuNPs,
with residual DNA double strand lesions used as a surrogate of
potentially lethal DNA damage. Residual DNA DEFs in the
presence of AuNPs ranged from 1.7 to 2.3, varying slightly as
a consequence of dose rate and/or total dose administered.73 The
primary limitation of this strategy, particularly with reference to
solid tumours including prostate tumours that frequently exhibit
poorly vascularized cores, is achieving sufﬁcient continual
nanoparticle delivery to achieve therapeutic gain. BT spacers are
routinely used in the clinic to improve spatial accuracy during
seed implantation. Spacers manufactured from slow release
polymers such as poly(lactic-co-glycolic acid) could be loaded
with AuNPs, providing an ideal platform for prolonged con-
tinual nanoparticle release localized to the tumour. The potential
therapeutic applicability of this approach has been modelled
with a complex variety of parameters inﬂuencing potential dose
enhancement. These include AuNP size, distance from a source,
time from implantation, degradation rate of the polymer and
activity/half-life of the BT seeds.40 Although this modelling study
presents the potential for therapeutic efﬁcacy, the lack of ade-
quate control over these variables will limit translation into
the clinic.
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Despite the presence of multiple in vitro studies demonstrating
AuNP radiosensitization, there is very little in vivo pre-clinical
evidence supporting their use in CaP treatment. At the time of
writing, to the authors’ knowledge, only one group has pub-
lished in vivo efﬁcacy. Wolfe et al73 developed targeted Au
nanorods (AuNRs), conjugated with bifunctionalized PEG
chains terminated with a zwitterionic goserelin peptide.
Tumours were actively targeted using goserelin, a synthetic
analogue of luteinizing hormone-releasing hormone (LHRH)
that binds with high afﬁnity to the LHRH receptors overex-
pressed on prostate tumours.74 Further increasing the clinical
relevance of this study, radiation treatments were delivered using
6-MV X-rays. Goserelin-targeted AuNRs conferred a signiﬁcant
dose enhancement of 1.32 over radiation only and 17% increase
over the unfunctionalized nanoparticle. The importance of this
differential between targeted and untargeted AuNRs was further
heightened in vivo. Radiosensitization efﬁcacy, deﬁned by delay
in the time for subcutaneous PC3 tumours to triple in volume,
was extended by 176 1 day in the goserelin-targeted AuNR
treatment group compared with radiation only, whereas the
untargeted AuNRs accumulating by passive targeting only (EPR)
produced no signiﬁcant delay in tumour growth over radiation
only. Furthermore, no signiﬁcant treatment-related adverse
events were reported.73 Owing to the relative simplicity, lack of
toxicity and therapeutic efﬁcacy of this approach, considered in
tandem with the frequency of use of external EBRT in CaP, this
strategy appears to represent the most likely translation of
nanoparticles into regular clinical use.
CONCLUSIONS
The radiotherapeutic management of CaP is rapidly changing
with IG-IMRT now the standard of care, increasing evidence for
combination strategies with BT and ADT and the emerging role
of MRI, dose-painting and adaptive treatment strategies. In
parallel, rapid advances in metal nanoparticle synthesis, target-
ing and manufacture are occurring. The integration of these
exciting advances should enable improvement in the manage-
ment of CaP in the years to come.
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